Janux Therapeutics has dosed the first patient at the City of Hope, US, in a Phase I trial of JANX008, designed to treat patients with advanced or metastatic solid tumours.

JANX008 will be evaluated in patients with these tumours, and including colorectal cancer, non-small cell lung cancer, squamous cell carcinoma of the head and neck, and renal cell carcinoma.

The open-label, multicentre dose escalation and dose expansion study will investigate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of JANX008.

It will assess the preliminary anti-tumour activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing epidermal growth factor receptor (EGFR).

Janux CEO and president David Campbell said: “JANX008 is the second therapeutic from our TRACTr platform to enter a first-in-human clinical trial, demonstrating the potential of our platform and the commitment of our team to address critical and urgent unmet needs for patients with advanced or metastatic solid tumours.”

An EGFR-directed T cell engager (TCE), JANX008 uses the company’s TRACTr platform to be administered in humans.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Janux chief medical officer Wayne Godfrey said: “JANX008 is designed to achieve tumour-selective T cell activation and tumour killing while sparing healthy tissues.

“Our preclinical data with JANX008 demonstrated tumour growth inhibition and lower toxicity levels when compared to an unmasked T cell engager.”